Ikaria Holdings, Inc., through its subsidiary INO Therapeutics LLC, announced today that Japan's Ministry of Health, Labor and Welfare (MHLW) has approved INOflo(R) (nitric oxide) for inhalation for improvement of hypoxic respiratory failure (HRF) with concurrent pulmonary hypertension in neonates. INOflo (brand name INOmax(R) in the United States) has been shown to improve oxygenation and reduce the need for ECMO, a highly invasive cardiopulmonary bypass procedure.
The details can be read here.
No comments:
Post a Comment